Immunovant COO granted stock options and RSUs

Gloria Melanie reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Gloria Melanie reported acquisition or exercise transactions in this Form 4 filing.

Immunovant, Inc. Chief Operating Officer Gloria Melanie received new equity awards. On April 7, 2026 she was granted options to buy 121,063 shares of common stock at $24.61 per share, expiring on April 7, 2036, and 83,671 restricted stock units at no cost.

The RSUs vest 25% on April 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments after that date, subject to continued service. The options vest 25% on April 1, 2027, with the balance vesting in thirty-six substantially equal monthly installments, also conditioned on continued service. After these grants, she directly owns 253,944 common shares.

Insider Trade Summary

Grant/Award: 204,734 shares

Grant/Award 2 txns

Insider Gloria Melanie

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	121,063	$0.00	$0.00
Grant/Award	Common Stock	83,671	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 121,063 contracts (Direct); Common Stock — 253,944 shares (Direct)

Footnotes (2)

1. F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
2. F2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Key Figures

RSU grant size: 83,671 units Option grant size: 121,063 shares Option exercise price: $24.61 per share +3 more

6 metrics

RSU grant size 83,671 units Restricted stock units granted April 7, 2026

Option grant size 121,063 shares Stock options granted April 7, 2026

Option exercise price $24.61 per share Stock option strike price

Options expiration April 7, 2036 Option expiration date

Shares owned after awards 253,944 shares Common stock directly owned post-transaction

Initial vesting date April 1, 2027 Start of RSU and option vesting schedules

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Stock Option (right to buy), vesting, +1 more

5 terms

restricted stock units ("RSUs") financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

vesting financial

"The RSUs will vest as to 25% of the total shares on April 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price": "24.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Immunovant (IMVT) report for Gloria Melanie?

Immunovant reported that Chief Operating Officer Gloria Melanie received equity awards on April 7, 2026. She was granted stock options and restricted stock units as part of compensation, increasing her direct common stock holdings to 253,944 shares after these awards.

How many stock options did Immunovant (IMVT) grant to its COO?

Gloria Melanie received options for 121,063 shares of Immunovant common stock at a $24.61 exercise price. These options vest 25% on April 1, 2027 and the remaining 75% in thirty-six substantially equal monthly installments, subject to her continued service.

What restricted stock unit (RSU) grant did Immunovant (IMVT) disclose for its COO?

Immunovant granted 83,671 restricted stock units to Chief Operating Officer Gloria Melanie under its 2019 Equity Incentive Plan. Each RSU represents one common share, vesting 25% on April 1, 2027 and the remainder in twelve substantially equal quarterly installments, contingent on continued service.

When do Gloria Melanie’s Immunovant (IMVT) RSUs and options vest?

Both awards begin vesting on April 1, 2027. RSUs vest 25% then, with the balance in twelve quarterly installments. Stock options vest 25% on the same date, with the remaining 75% vesting in thirty-six substantially equal monthly installments, subject to ongoing employment.

What is the exercise price and expiration date of Immunovant (IMVT) COO’s options?

The stock options granted to Gloria Melanie have a $24.61 per share exercise price and expire on April 7, 2036. She must remain in continuous service and the options must vest before she can exercise them to acquire Immunovant common shares.

How did these grants change Gloria Melanie’s Immunovant (IMVT) share holdings?

Following the April 7, 2026 equity awards, Gloria Melanie directly holds 253,944 shares of Immunovant common stock. This figure reflects her post-transaction ownership as reported, not including the 121,063 option shares and 83,671 RSUs that remain subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gloria Melanie

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		A		83,671(1)	A	$0	253,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.61	04/07/2026		A		121,063		(2)	04/07/2036	Common Stock	121,063	$0	121,063	D

Explanation of Responses:

1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Melanie Gloria	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)